布拉氏酵母菌散联合蒙脱石散治疗小儿急性腹泻的临床疗效与安全性

Clinical efficacy and safety of saccharomyces boulardii powder combined with montmorillonite powder in treatment of acute diarrhea in children

目的探讨布拉氏酵母菌散联合蒙脱石散治疗小儿急性腹泻的临床疗效与安全性。方法选取2014年3月～2015年7月丽水市人民医院诊断为急性腹泻的患儿68例,按随机数字表法分为2组：对照组34例,在抗炎、补液、支持等基础治疗基础上给予蒙脱石散;实验组34例,在基础治疗上联合应用布拉氏酵母菌散和蒙脱石散,均治疗6 d。观察2组患者治疗前后大便次数、腹泻控制时间、腹泻总时间和不良反应。结果治疗后,实验组每天大便次数明显低于对照组（P〈0.05）;实验组腹泻控制时间和腹泻总时间明显低于对照组（P〈0.05）;实验组临床总有效率为91.18%,明显高于对照组的73.53%（P〈0.05）。结论布拉氏酵母菌散联合蒙脱石散对小儿急性腹泻能缩短腹泻时间,具有较好的临床疗效。

Objective To investigate the clinical efficacy and safety of montmorillonite powder combined with saccharomyces boulardii powder in treatment of acute diarrhea in children. Methods A total of 68 children with acute diarrhea from March 2014 to July 2015 in Lishui People＇s Hospital were collected and randomly divided into experiment group and control group,with 34 cases in each group. Patients in control group were treated by montmorillonite on the basis of anti-inflammation,fluid infusion,support and other symptomatic treatment; patients in experiment group were treated saccharomyces boulardii powder combined with montmorillonite powder on the base of clinical routine treatment,the course was 6 days. The stool frequency,diarrhea control time,diarrhea total time and incidence of adverse reactions rate of two groups before and after treatment were observed,and the validity and safety were compared. Results After 6 days treatment,the daily stool frequency of experiment group were significantly lower than control group（ P〈0. 05）; diarrhea control time and diarrhea total time of experiment group were significantly lower than control group（ P〈0. 05）. The clinical efficacy of experiment group was 91. 18%,higher than 73. 53% of control group（ P〈0. 05）. Conclusion Saccharomyces boulardii powder combined with montmorillonite powder on acute diarrhea in children with good clinical efficacy.